Neurosteroid offers clues to brain changes linked to depression
UTSW and UT Dallas researchers uncover evidence that pregnenolone alters functional connectivity between brain regions
DALLAS – Nov. 18, 2026 – UT Southwestern Medical Center researchers and colleagues, including two at UT Dallas, have found evidence that pregnenolone – a naturally occurring steroid hormone the body produces from cholesterol – may alter patterns of communication between key brain regions involved in depression and cognitive control.
The study, conducted with the UT Dallas Center for BrainHealth and published in the Journal of Clinical Psychiatry, could potentially lead to the development of a brain-based marker of neurosteroid effects, enhancing the medical community’s understanding of depression and providing insights that could inform future treatment approaches.
“Previous studies have suggested that pregnenolone could be an effective treatment for depression in people with bipolar disorder, but we lacked insight into exactly how it affects neural circuits across the brain, especially those involved in depression,” said corresponding author E. Sherwood Brown, M.D., Ph.D., M.B.A., Professor of Psychiatry in the Peter O’Donnell Jr. Brain Institute at UT Southwestern. “These findings bring us one step closer to developing proven neuroimaging biomarkers that would enable us to see exactly how pregnenolone changes functional connectivity between regions of the brain in people with depression – and how we might shape those changes to benefit patients.”
The study followed 29 women with mild to moderate major depressive disorder in a double-blind, placebo-controlled crossover trial of pregnenolone. Participants received three seven-day treatment conditions – 500 or 800 milligrams (mg) per day of pregnenolone or placebo – taken orally. Testing was performed via serum samples and functional MRI (fMRI) exams, a brain-imaging technique that enables researchers to study brain activity by measuring changes in blood flow and oxygen levels. The final fMRI analysis included 11 participants who had usable data from all three treatments.
Compared with the placebo, participants taking 500 mg/day of pregnenolone had reduced functional connectivity between the amygdala and left frontal pole, the regions of the brain involved in emotional processing and cognitive control. This change may reflect improved emotional regulation, a process that is often impaired in people with depression. The findings may help explain how pregnenolone and related neurosteroids could have antidepressant effect.
Intriguingly, the connectivity change was seen with the 500 mg dose but not the 800 mg dose, suggesting that more pregnenolone does not necessarily produce a greater effect on these brain circuits. Both doses were well tolerated, with no serious adverse events reported. Blood tests also showed that both doses of pregnenolone significantly increased levels of allopregnanolone, a downstream neurosteroid involved in regulating brain signaling.
“This study gives us a better understanding of how neurosteroids may influence brain connectivity in women with depression, an area that hasn’t been studied enough,” said contributing author Francesca Filbey, Ph.D., Deputy Director at the UT Dallas Center for BrainHealth and the Bert Moore Endowed Chair and Professor of the School of Behavioral and Brain Sciences at UT Dallas.
The next steps for researchers will be to determine whether observed connectivity changes are associated with improvement in depressive symptoms or cognition and to replicate the findings in a larger sample.
“Ultimately, the goal is to establish whether pregnenolone or related compounds can provide a clinically meaningful treatment option,” Dr. Brown said. “These findings open the door to future research to determine whether these brain changes ultimately translate into meaningful improvements for patients with depression.”
Other researchers from the UTSW Department of Psychiatry who contributed to this study are Elena Ivleva, M.D., Ph.D., Professor; Jayme M. Palka, Ph.D., Assistant Professor; Zena Patel, M.P.A.S., PA-C.; and Traci Holmes, B.S., Research Programs Manager.
Dr. Brown, a Distinguished Teaching Professor, holds the Lou and Ellen McGinley Distinguished Chair in Psychiatric Research and the Aradine S. Ard Chair in Brain Science. He is also Vice Chair for Clinical Research in the Department of Psychiatry and Director of the Psychoneuroendocrine Research Program at UTSW.
This study was funded through a grant from the National Center for Complementary and Integrative Health of the National Institutes of Health (R61AT009625).
About UT Southwestern Medical Center
UT Southwestern, one of the nation’s premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty members have received six Nobel Prizes and include 28 members of the National Academy of Sciences, 26 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of nearly 3,400 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians in more than 80 specialties care for more than 143,000 hospitalized patients, attend to more than 470,000 emergency room cases, and oversee nearly 5.3 million outpatient visits a year.
About Center for BrainHealth
Center for BrainHealth®, part of The University of Texas at Dallas, is a nonprofit translational research institute committed to optimizing, preserving, restoring, and measuring brain health across the lifespan. Scientific discovery uncovering the dynamic relationship between lifestyle factors, biological markers, brain training, and cognitive performance is translated quickly into practical innovations, empowering people of all ages to thrive and unlock their brain potential.